Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies.
To characterize the contribution of the human flavin-containing monooxygenase form 3 (FMO3) in the metabolism and disposition of drugs and xenobiotics, we determined the single nucleotide polymorphisms in the coding region and adjacent splice junctions of FMO3 in 134 African Americans and 120 Caucasians from the United States. In the regions examined, DNA resequencing or high throughput MassEXTEND studies coupled with mass spectrometric genotyping showed that 12 sites of variation were present. Three variants encoding synonymous mutations and four polymorphisms were observed in the noncoding region. Another three variants, Lys158-FMO3, Met257-FMO3 and Gly308-FMO3, previously reported in similar populations, were prominent polymorphisms. Two new polymorphisms, His132-FMO3 and Pro360-FMO3, were identified in this study. Both variants were found only in African Americans. To evaluate the effect of the amino acid substitutions on the function of FMO3, each amino acid substitution was introduced by site-directed mutagenesis into a wild-type FMO3 cDNA. Selective functional activity was studied with methimazole, trimethylamine, and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl) phenothiazine. Both His132-FMO3 and Pro360-FMO3 variants were able to metabolize the substrates examined. Compared with wild-type FMO3, the His132-FMO3 was less catalytically efficient. The His132-FMO3 variant moderately altered the catalytic efficiency of FMO3 (decrease of 30%, 60% and 6% with methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, respectively). The Pro360-FMO3 variant was more catalytically efficient than wild-type FMO3. Pro360-FMO3 oxygenated methimazole, trimethylamine and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, respectively, 3-, 5- and 2-fold more efficiently than wild-type FMO3. Based on the functional activity of the variant FMO3 enzymes, it is likely that population differences exist for compounds primarily metabolized by FMO3.
Lattard
Virginie
V
Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA.
Zhang
Jun
J
Tran
Quyen
Q
Furnes
Bjarte
B
Schlenk
Daniel
D
Cashman
John R
JR
D000328:Adult; D001741:Black or African American / Q000235:genetics*; D000595:Amino Acid Sequence; D004247:DNA / Q000032:analysis; D018076:DNA, Complementary / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005787:Gene Frequency; D005819:Genetic Markers; D005838:Genotype; D006801:Humans; D008297:Male; D008713:Methimazole / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D008744:Methylamines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000652:urine; D010105:Oxygenases / Q000235:genetics* / Q000378:metabolism; D010640:Phenothiazines / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D017422:Sequence Analysis, DNA / Q000379:methods; D014481:United States; D044465:White People / Q000235:genetics*
D018076:DNA, Complementary; D005819:Genetic Markers; D008744:Methylamines; D010640:Phenothiazines; D008713:Methimazole; D004247:DNA; D010105:Oxygenases; C020066:dimethylaniline monooxygenase (N-oxide forming); C023336:trimethylamine